EMA Considers How To Verify Potency Of Next-Generation COVID-19 Vaccines
Executive Summary
Companies approaching the European Medicines Agency with their development plans for new COVID-19 vaccines are being asked to consider immunobridging studies if placebo-controlled trials are not feasible.
You may also be interested in...
EMA Head Calls For New Global Workshop On Variant Vaccines
Five vaccines and six therapeutics are now available for use against COVID-19 in the EU, but as Omicron shows, there is likely to be a need for new kinds of vaccines against future virus variants.
COVID-19 Vaccines: Regulatory Consortium Addresses Way Forward With Immunobridging Studies
Drug regulators from five countries have outlined their joint expectations on the data companies must submit for the approval of next-generation COVID-19 vaccines if they opt for immunobridging studies instead of large-scale efficacy trials.
COVID-19 Vaccine Studies Should Look Beyond Neutralizing Antibodies To Assess Variants’ Impact
Cellular responses and other potential immune correlates of protection could be better measurements of efficacy, Janssen’s vaccine discovery head argues at BIO.